← All trials
NCT04747054
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Sep 15, 2025
- Completion date
- Sep 15, 2029
- First posted
- Feb 10, 2021
- Last posted
- Sep 28, 2021
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- UNICANCERLead sponsor
- GROUPE ONCOLOGIE RADIOTHERAPIE TETE ET COUCollaborator
- Institut Gustave RoussyOverall official - principal investigator
- National Cancer Institute, FranceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.